Trial intelligence / Profile preview

Phase 3 randomized double-blind placebo-controlled adjuvant selpercatinib after definitive local therapy for RET fusion-positive NSCLC

MOH_2021-10-13_010321Phase 3Recruiting

Sponsor

ג'ני מלניצנקו

Start

Oct 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1